Tema Etfs LLC Buys Shares of 19,040 Ascendis Pharma A/S (NASDAQ:ASND)

Tema Etfs LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 19,040 shares of the biotechnology company's stock, valued at approximately $2,621,000.

Several other institutional investors also recently bought and sold shares of ASND. Point72 Asia Singapore Pte. Ltd. bought a new position in Ascendis Pharma A/S during the fourth quarter valued at $28,000. Janus Henderson Group PLC lifted its position in Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Ascendis Pharma A/S during the fourth quarter valued at $2,123,000. Bellevue Group AG bought a new position in Ascendis Pharma A/S during the fourth quarter valued at $344,000. Finally, Alyeska Investment Group L.P. lifted its position in Ascendis Pharma A/S by 34.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 155,000 shares of the biotechnology company's stock valued at $21,339,000 after purchasing an additional 40,000 shares during the last quarter.

Ascendis Pharma A/S Stock Up 0.8%

ASND traded up $1.24 on Tuesday, reaching $161.57. 247,021 shares of the company traded hands, compared to its average volume of 492,835. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The firm has a fifty day simple moving average of $157.53 and a two-hundred day simple moving average of $143.01. The company has a market cap of $9.85 billion, a P/E ratio of -22.76 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Finally, Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $180.00 to $250.00 in a report on Monday, May 5th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $216.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.